Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2)
- PMID: 32369402
- PMCID: PMC7267743
- DOI: 10.1177/0004563220928361
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2)
Abstract
Since the first cases of atypical pneumonia linked to the Huanan Seafood Wholesale Market in Wuhan, China, were described in late December 2019, the global landscape has changed radically. In March 2020, the World Health Organization declared COVID-19 a global pandemic, and at the time of writing this review, just over three million individuals have been infected with more than 200,000 deaths globally. Numerous countries are in 'lockdown', social distancing is the new norm, even the most advanced healthcare systems are under pressure, and a global economic recession seems inevitable. A novel coronavirus (SARS-CoV-2) was identified as the aetiological agent. From experience with previous coronavirus epidemics, namely the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) in 2004 and 2012 respectively, it was postulated that the angiotensin-converting enzyme-2 (ACE2) receptor is a possible port of cell entry. ACE2 is part of the renin-angiotensin system and is also associated with lung and cardiovascular disorders and inflammation. Recent studies have confirmed that ACE2 is the port of entry for SARS-CoV-2. Male sex, advanced age and a number of associated comorbidities have been identified as risk factors for infection with COVID-19. Many high-risk COVID-19 patients with comorbidities are on ACE inhibitors and angiotensin receptor blockers, and this has sparked debate about whether to continue these treatment regimes. Attention has also shifted to ACE2 being a target for future therapies or vaccines against COVID-19. In this review, we discuss COVID-19 and its complex relationship with ACE2.
Keywords: COVID-19; SARS-CoV-2; angiotensin-converting enzyme 2; renin-angiotensin system.
Figures
Similar articles
-
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25. Hypertension. 2020. PMID: 32208987 Free PMC article.
-
Covid-19: the renin-angiotensin system imbalance hypothesis.Clin Sci (Lond). 2020 Jun 12;134(11):1259-1264. doi: 10.1042/CS20200492. Clin Sci (Lond). 2020. PMID: 32507883 Free PMC article. Review.
-
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 32464637 Free PMC article. Review.
-
COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?J Intern Med. 2020 Oct;288(4):410-421. doi: 10.1111/joim.13101. Epub 2020 Jun 8. J Intern Med. 2020. PMID: 32459372 Free PMC article. Review.
-
Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.Eur Respir J. 2020 Jul 9;56(1):2000912. doi: 10.1183/13993003.00912-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32341103 Free PMC article. Review.
Cited by
-
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.Biosci Rep. 2020 Oct 30;40(10):BSR20202856. doi: 10.1042/BSR20202856. Biosci Rep. 2020. PMID: 33063092 Free PMC article. Review.
-
Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies.Heliyon. 2024 Feb 2;10(3):e25734. doi: 10.1016/j.heliyon.2024.e25734. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38356603 Free PMC article. Review.
-
N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study.Caspian J Intern Med. 2023 Summer;14(3):543-552. doi: 10.22088/cjim.14.3.553. Caspian J Intern Med. 2023. PMID: 37520878 Free PMC article.
-
Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.Rev Med Virol. 2021 Sep;31(5):1-12. doi: 10.1002/rmv.2213. Epub 2021 Jan 10. Rev Med Virol. 2021. PMID: 33426683 Free PMC article. Review.
-
Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19.J Pers Med. 2021 Dec 1;11(12):1264. doi: 10.3390/jpm11121264. J Pers Med. 2021. PMID: 34945736 Free PMC article.
References
-
- Johns Hopkins University & Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE), https://coronavirus.jhu.edu/map.html (2020, accessed 27 April 2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous